Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors
- Tuesday, May 4, 2021, 7:14
- PR Newswire
- Add a comment
FARMINGDALE, N.Y., May 4, 2021 /PRNewswire/ — Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies for cancer, today announced the appointment of innovative oncology leader Johanna Kaufmann, Ph.D., as Executive Vice…
About the Author
admin has written 20523 stories on this site.